Aclaris Therapeutics, Inc. (ACRS): who owns it and who trades it
As of Nov 16, 2026, ACRS insiders reported 1 open-market sale worth $1.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Braden Michael Leonard (10% owner), with $1.4M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aclaris Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ACRS
149 funds and institutions reported ACRS shares worth $643M at the end of Q2 2026, about 87% of the company. The largest holder is Ra Capital Management, L.P. with 9.1%.
Funds and institutions (13F) 87%Everyone else 13%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.72M | 9.11% | $67.3M | +87% |
| BML Capital Management, LLC | 11.97M | 8.57% | $63.3M | -16% |
| BlackRock, Inc. | 10.04M | 7.19% | $53.1M | +36% |
| Deep Track Capital, LP | 9.35M | 6.69% | $49.4M | No change |
| Vivo Capital, LLC | 6.69M | 4.79% | $35.4M | +0% |
| Vanguard Capital Management LLC | 5.82M | 4.17% | $30.8M | +13% |
| Frazier Life Sciences Management, L.P. | 4.93M | 3.53% | $26.1M | No change |
| Rock Springs Capital Management LP | 4.33M | 3.10% | $22.9M | -3% |
| Adage Capital Partners Gp, L.l.c. | 4.07M | 2.91% | $21.5M | +5% |
| Decheng Capital LLC | 4.04M | 2.89% | $21.4M | No change |
| Kalehua Capital Management LLC | 3.66M | 2.62% | $19.4M | +16% |
| State Street Corp | 3.26M | 2.33% | $17.2M | +62% |
| Geode Capital Management, LLC | 3.19M | 2.28% | $16.9M | +32% |
| Braidwell LP | 2.14M | 1.53% | $11.3M | +26% |
| Balyasny Asset Management L.P. | 2.02M | 1.45% | $10.7M | -40% |
| Silverarc Capital Management, LLC | 1.95M | 1.39% | $10.3M | – |
| Citadel Advisors LLC | 1.76M | 1.26% | $9.3M | -22% |
| Jones Hill Capital LP | 1.76M | 1.26% | $9.3M | – |
| Acadian Asset Management LLC | 1.64M | 1.18% | $8.7M | +7% |
| Palo Alto Investors LP | 1.61M | 1.16% | $8.5M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ACRS insiders reported $0 of open-market purchases and $1.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard | 10% owner | Sale | 300,000 | $4.53 | $1.4M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Braden Michael Leonard | 10% owner | – | $1.4M | Apr 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ACRS short interest
Moderate short interest. 7.3% of ACRS shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 58%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.57M ACRS shares were sold short, 7.3% of the shares outstanding, down 23.0% from the report before. At the average daily volume of 2.88M shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.57M | 7.30% | -23% | 2.88M | 4.0 |
| Oct 15, 2026 | 15.03M | 10.21% | -17% | 5.10M | 3.0 |
| Sep 30, 2026 | 18.19M | 12.36% | +13% | 2.81M | 6.5 |
| Sep 15, 2026 | 16.08M | 10.92% | +6% | 2.52M | 6.4 |
| Aug 31, 2026 | 15.18M | 10.31% | +3% | 1.75M | 8.7 |
| Aug 14, 2026 | 14.71M | 9.99% | +7% | 2.10M | 7.0 |
| Jul 31, 2026 | 13.77M | 9.36% | +3% | 1.59M | 8.7 |
| Jul 15, 2026 | 13.36M | 9.56% | +17% | 1.93M | 6.9 |
| Jun 30, 2026 | 11.40M | 8.17% | +28% | 2.67M | 4.3 |
| Jun 15, 2026 | 8.90M | 6.37% | +10% | 1.31M | 6.8 |
| May 29, 2026 | 8.08M | 5.78% | +10% | 915,723 | 8.8 |
| May 15, 2026 | 7.35M | 5.26% | -7% | 1.31M | 5.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aclaris Therapeutics company events
Aclaris Therapeutics filed 13 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 27, 2026AgreementAclaris Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share and… Filing
- Oct 27, 2026AnnouncementAclaris Therapeutics, Inc. issued a press release announcing primary analysis results from the Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma. Filing
- Aug 6, 2026AgreementAclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. under which the Company may offer and sell, from time to time at the Company’s sole discretion, shares of common stock through Leerink and Cantor as sales… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 28, 2026AnnouncementThe Company issued a press release announcing the ATI-052 Results & ATI-2138 Trial. Filing
- Mar 11, 2026AnnouncementShared information with investors. Filing
- Mar 10, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 6, 2026AnnouncementInterim Phase 1a SAD/MAD Results The Interim Results announced in the press release are summarized below. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aclaris Therapeutics financials
Famous investors that hold ACRS
3 of the 50 well-known investors we track reported holding ACRS in their latest 13F filing. The largest position is Ken Griffin's, worth $9.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.78M | $9.3M | 0.0% | +1% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 82,812 | $436K | 0.0% | -90% |
| Israel Englander · Millennium Management | Q3 2026 | 50,673 | $267K | 0.0% | -90% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ACRS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Biosion, Inc. | 13G/A | 4.7% |
| Nov 16, 2026 | Biosion, Inc. | 13G/A | 4.7% |
Questions about Aclaris Therapeutics, Inc. (ACRS) stock
Who owns the most ACRS stock?
The largest reported owner of Aclaris Therapeutics, Inc. (ACRS) is Ra Capital Management, L.P., with 9.1% of the company. In total, 149 funds and institutions reported holding ACRS at the end of Q2 2026, together about 87% of the shares. See the largest owners.
Are ACRS insiders buying or selling?
In the last 12 months, ACRS insiders reported no open-market purchases and 1 sale worth $1.4M. The latest trade was on Apr 23, 2026. See every trade.
What is the short interest in ACRS?
As of Oct 30, 2026, 11.57M ACRS shares were sold short, 7.3% of the shares outstanding, down 23.0% from the report before. At the average daily volume of 2.88M shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold ACRS?
3 of the 50 well-known investors we track reported ACRS in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $9.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.